Taysha Gene Therapies (TSHA) Non-Current Assets (2020 - 2026)
Taysha Gene Therapies (TSHA) posted Non-Current Assets of $18.1 million for Q1 2026, down 3.06% sequentially from $18.7 million in Q4 2025, and up 2.53% YoY from $17.7 million in Q1 2025.
Taysha Gene Therapies (TSHA) Non-Current Assets (2020 - 2026) Analysis & Trends
Taysha Gene Therapies has reported Non-Current Assets for 7 years, with the latest figure at $18.1 million in Q1 2026.
- Quarterly Non-Current Assets rose 2.53% year-over-year to $18.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $70.4 million (down 7.88% YoY) and the FY2025 annual result came in at $18.7 million, up 2.41% from the prior year.
- Non-Current Assets slipped to $18.1 million in Q1 2026 per TSHA's latest filing, from $18.7 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $68.5 million in Q3 2022 and troughed at $16.6 million in Q3 2025.
- A 5-year average of $29.2 million and a median of $22.4 million in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2023: Non-Current Assets soared 1746.41% in 2022, then plunged 65.0% in 2023.
- Over 5 years, Non-Current Assets stood at $29.9 million in 2022, then declined by 23.43% to $22.9 million in 2023, then decreased by 20.25% to $18.2 million in 2024, then gained by 2.41% to $18.7 million in 2025, then decreased by 3.06% to $18.1 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $18.1 million, $18.7 million, and $16.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Taysha Gene Therapies | 1.94 Bn | 1.94 Bn | - | 9.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.00 Mn |
| Mar 31, 2026 | 18.10 Mn |
| Dec 31, 2025 | 18.67 Mn |
| Sep 30, 2025 | 16.60 Mn |
| Jun 30, 2025 | 17.07 Mn |
| Mar 31, 2025 | 17.65 Mn |
| Dec 31, 2024 | 18.23 Mn |
| Sep 30, 2024 | 18.66 Mn |
| Jun 30, 2024 | 21.92 Mn |
| Mar 31, 2024 | 22.40 Mn |
| Dec 31, 2023 | 22.86 Mn |
| Sep 30, 2023 | 23.96 Mn |
| Jun 30, 2023 | 27.43 Mn |
| Mar 31, 2023 | 29.24 Mn |
| Dec 31, 2022 | 29.86 Mn |
| Sep 30, 2022 | 68.47 Mn |
| Jun 30, 2022 | 65.50 Mn |
| Mar 31, 2022 | 59.09 Mn |
| Dec 31, 2021 | 54.35 Mn |
| Sep 30, 2021 | 43.87 Mn |